Clinical trials: Leukemia, Lymphocytic, Acute, L1
Leukemia
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Acute Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses…
- Trial name
- NCT00008190
- Testing
- aldesleukin, filgrastim, busulfan
- Where
- United States
- Sponsor
- Herbert Irving Comprehensive Cancer Center
Leukemia
Resistance to Methotrexate in Patients With Acute Lymphoblastic Leukemia in Relapse or Remission
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about cancer and the development of drug resistance in patients.
- Trial name
- NCT00899899
- Testing
- microarray analysis, reverse transcriptase-polymerase chain reaction, laboratory biomarker analysis
- Volunteers
- 135 people
- Sponsor
- Children's Oncology Group
Leukemia, Myelodysplastic Syndromes
Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia
RATIONALE: Giving chemotherapy, such as busulfan, fludarabine, and melphalan, before a donor umbilical cord blood stem cell transplant helps stop the growth of abnormal or cancer cells and prepares the patient's bone marrow for…
- Conditions
- Leukemia, Myelodysplastic Syndromes, Childhood Acute Myeloid Leukemia in Remission, Recurrent Childhood Acute Myeloid Leukemia
- Trial name
- NCT00357565
- Testing
- filgrastim, busulfan, cyclosporine
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Leukemia, Myeloid, Acute, Leukemia, Lymphoblastic, Acute, L1
Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation
This is a Phase 1, open-label, single center study of short-course oral venetoclax therapy prior to non-myeloablative conditioning with fludarabine and cyclophosphamide in subjects with haematological malignancies who are planned…
- Conditions
- Leukemia, Myeloid, Acute, Leukemia, Lymphoblastic, Acute, L1, Leukemia, Lymphoblastic, Acute, L2, Myelodysplastic Syndromes
- Trial name
- VICTORY (NCT05005299)
- Testing
- Venetoclax, Fludarabine, Cyclophosphamide
- Where
- Australia
- Volunteers
- 18 people
- Sponsor
- Melbourne Health
Leukemia
AT9283 in Treating Young Patients With Relapsed or Refractory Acute Leukemia
RATIONALE: AT9283 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I/IIa clinical trial is studying the side effects and best dose of AT9283 in treating young…
- Trial name
- NCT01431664
- Testing
- multikinase inhibitor AT9283, laboratory biomarker analysis, pharmacological study
- Where
- 5 sites in United Kingdom
- Volunteers
- 7 people
- Sponsor
- Cancer Research UK
COVID-19 Vaccines, Telemedicine
Improving Pediatric COVID-19 Vaccine Uptake Using an mHealth Tool
This study will determine the effectiveness of a vaccine communication mobile health app on parental decisions to vaccinate their children against coronavirus disease 2019 (COVID-19).
- Conditions
- COVID-19 Vaccines, Telemedicine, Vaccine Hesitancy, Pediatric ALL
- Trial name
- MoVeUP (NCT05386355)
- Testing
- COVID-19 Vaccine Uptake App, General Health App
- Where
- 15 sites in United States
- Volunteers
- 1,934 people, healthy volunteers welcome
- Sponsor
- IDeA States Pediatric Clinical Trials Network
Leukemia, Lymphoma
Monoclonal Antibody Therapy in Treating Patients With Recurrent Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00004858
- Testing
- B43-genistein immunoconjugate
- Where
- 3 sites in United States
- Sponsor
- Parker Hughes Cancer Center
Acute Leukemias of Ambiguous Lineage, Acute Undifferentiated Leukemia
Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia
This phase I trial is studying the side effects and best dose of obatoclax mesylate when given together with vincristine sulfate, doxorubicin hydrochloride, and dexrazoxane hydrochloride in treating young patients with relapsed…
- Conditions
- Acute Leukemias of Ambiguous Lineage, Acute Undifferentiated Leukemia, Angioimmunoblastic T-cell Lymphoma, Blastic Phase Chronic Myelogenous Leukemia
- Trial name
- NCT00933985
- Testing
- dexrazoxane hydrochloride, doxorubicin hydrochloride, obatoclax mesylate
- Where
- 20 sites in United States, Canada
- Volunteers
- 22 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Myeloproliferative Disorders, Leukemia
Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer
RATIONALE: Giving chemotherapy drugs and total-body irradiation before a donor stem cell helps stop the growth of cancer or abnormal cells. It may also stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT00003816
- Testing
- anti-thymocyte globulin, busulfan, carboplatin
- Where
- United States
- Volunteers
- 361 people
- Sponsor
- Roswell Park Cancer Institute
Leukemia, Lymphoma
Peripheral Blood Lymphocyte Therapy to Prevent Lymphoproliferative Disorders Caused by Epstein-Barr Virus in Patients Who Have Undergone Transplantation
RATIONALE: Peripheral blood lymphocyte therapy may be effective in the treatment and prevention of Epstein-Barr virus infection following transplantation.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00005606
- Testing
- allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes, autologous Epstein-Barr virus-specific cytotoxic T lymphocytes
- Where
- United States
- Sponsor
- Northwestern University
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation
RATIONALE: Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill tumor cells.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00005641
- Testing
- anti-thymocyte globulin, busulfan, cyclophosphamide
- Where
- United States
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Heart; Surgery, Heart, Functional Disturbance as Result, Pediatric ALL
Oblique Versus Transverse Orientation Approach for Internal Jugular Venous Cannulation in Pediatrics
this study aimed to compare oblique versus transverse orientation approach in jugular venous cannulation in term of cannulation success in pediatric heart surgery patients
- Trial name
- NCT05656937
- Testing
- internal jugular venous cannulation
- Where
- Indonesia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Universitas Indonesia
Relapsed Childhood ALL, Relapsed Childhood Lymphoblastic Lymphoma
Expanded Access Program of Venetoclax and Navitoclax for Pediatric Patients with Relapsed or Refractory ALL or LL
The overall goal of this expanded access program is to provide Venetoclax and Navitoclax to patients with acute lymphocytic leukemia (ALL) or lymphoblastic lymphoma (LL) who have exhausted standard treatments.
- Trial name
- NCT05215405
- Testing
- Venetoclax, Navitoclax
- Where
- United States
- Sponsor
- Kathleen Ludwig
Leukemia, Lymphoma
BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma
RATIONALE: BL22 immunotoxin can locate tumor cells and kill them without harming normal cells. BL22 immunotoxin may be effective in treating relapsed or refractory acute lymphoblastic leukemia and non-Hodgkin's lymphoma.
- Trial name
- NCT00077493
- Testing
- BL22 immunotoxin, antibody-drug conjugate therapy, immunotoxin therapy
- Where
- United States
- Volunteers
- 95 people
- Sponsor
- MedImmune LLC
Childhood Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2019 Pilot
THE PURPOSE OF THE STUDY is to optimize the therapy of patients with primary B-cell precursor acute lymphoblastic leukemia (BCP-ALL) by including monoclonal bispecific antibodies in post-induction treatment with simultaneous…
- Trial name
- NCT04723342
- Testing
- Blinatumomab
- Where
- 4 sites in Russia
- Volunteers
- 180 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Acute Lymphoblastic Leukemia
The GD-2008 ALL Protocol for Childhood Acute Lymphoblastic Leukemia
The Guangdong work group of childhood acute lymphoblastic leukemia (ALL) therapy was set up in October 2002. The investigators treated the childhood ALL with a GZ2002 protocol since the year 2002, and the protocol was mainly…
- Trial name
- NCT00846703
- Testing
- 6-mercaptopurine, Methotrexate, 6-mercaptopurine, Methotrexate, Vincristine, Dexamethasone
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Sun Yat-sen University
Acute Lymphoblastic Leukemia
Severe Toxicity Free Survival Following Childhood Acute Lymphoblastic Leukemia
The goal of this observational study is to quantify the burden of particularly severe, long-term adverse effects in childhood acute lymphoblastic leukemia (ALL) survivors.
- Trial name
- NCT05639673
- Where
- Denmark
- Volunteers
- 5,000 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Leukemia, Metabolic Syndrome X
Adipokines as Predictors of the Metabolic Syndrome in ALL Survivors
Background: Acute Lymphoblastic Leukemia (ALL) is the most common malignancy in children. It accounts for 25% of all childhood cancers. Peak incidence occurs between 2 to 5 years of age.
- Trial name
- NCT00566566
- Testing
- sample without DNA
- Volunteers
- 150 people
- Sponsor
- Sheba Medical Center
Acute Lymphoblastic Leukemia
Treatment for Executive Dysfunction in Adult Survivors of Childhood Acute Lymphoblastic Leukemia
A common and potentially debilitating late effect of childhood cancer treatment is neurocognitive impairment, frequently in the domain of executive dysfunction, which can limit educational attainment, employment, and quality of…
- Trial name
- NCT02336282
- Testing
- transcranial Direct Current Stimulation (tDCS), Cognitive Assessment, Brain Games Stimulation
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- St. Jude Children's Research Hospital
Acute Lymphoblastic Leukemia, Pediatric, Relapsed Acute Lymphoblastic Leukemia
Palbociclib in Combo w/Chemotherapy in Peds Relapsed/Refractory Acute Lymphoblastic Leukemia
With this research study has following goals To confirm the highest tolerable dose of palbociclib in combination with chemotherapy is safe and well-tolerated.
- Conditions
- Acute Lymphoblastic Leukemia, Pediatric, Relapsed Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia
- Trial name
- NCT04996160
- Testing
- Palbociclib, Dexamethasone, Bortezomib
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Tanja Andrea Gruber